Symeres welcomes Dr. André de Vries
At Symeres, we’re always looking to support our clients with novel and innovative ideas. Dr. André de Vries joined our ranks as of January 1, 2022.
Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II
In 2016, Stefan Krauss and Jo Waaler (University Hospital of Oslo, Norway) approached Symeres to optimize […]
Chiralix, a Symeres company
Richard Baauw joined Symeres in 2017, along with his company Chiralix. Chiralix focused on the synthesis of optically active compounds.
C&ENs 10 Start-Ups to Watch
This week, the 2021 Chemical & Engineering News list of ‘10 Start-Ups to Watch’ came out. […]
Expanding the toolbox: Resolving racemates
Symeres has quite a legacy when it comes to university collaborations. For many years, we’ve been […]
From CRO client to CRO employee: An interview with Dr. Chris Teleha
While working in big pharma, Dr. Chris Teleha spent years working with CROs in the development […]
On the road again: Experiencing BioTrinity 2021 as our first 2021 live event
COVID-19 has changed how we interact with people and has forced us to re-evaluate how we […]
The ‘Art of API’
The timely availability of high-quality APIs accelerates further investigation by our clients. To meet these pressing API needs, Symeres enables a route-scouting investigation for the API of interest.
Renewal of the GMP certificate for Symeres Prague
This spring, Symeres Prague was audited by the national control authority SÚKL. After this audit, our […]
